Jonsson Comprehensive Cancer Center
🇺🇸United States
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
Early Phase 1
Recruiting
- Conditions
- Prostate CarcinomaRecurrent Prostate Carcinoma
- Interventions
- Drug: 99mTc-based PSMA Imaging and Surgery AgentProcedure: Computed TomographyProcedure: Single Photon Emission Computed Tomography
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04857502
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Phase 1
Withdrawn
- Conditions
- Recurrent GlioblastomaRecurrent GliosarcomaSupratentorial GliosarcomaRecurrent Supratentorial Glioblastoma
- Interventions
- Drug: Akt/ERK Inhibitor ONC201Radiation: Radiation TherapyProcedure: Resection
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT04854044
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
Early Phase 1
Terminated
- Conditions
- Advanced Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaBCLC Stage B Hepatocellular CarcinomaRefractory Hepatocellular Carcinoma
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT04777708
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Recruiting
- Conditions
- Prostate Carcinoma
- Interventions
- Procedure: 3 Tesla Magnetic Resonance ImagingOther: Electronic Health Record Review
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 275
- Registration Number
- NCT04765150
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer
Recruiting
- Conditions
- Thyroid Gland NoduleThyroid Gland Carcinoma
- Interventions
- Procedure: Biospecimen CollectionOther: Electronic Health Record Review
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 250
- Registration Number
- NCT04742608
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Phase 2
Recruiting
- Conditions
- Cervical Squamous Intraepithelial Neoplasia 2Cervical Intraepithelial NeoplasiaCervical Squamous Cell Carcinoma In Situ
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04712851
- Locations
- 🇺🇸
University of California at Los Angeles / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer
Not Applicable
Terminated
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Behavioral: Cognitive Behavior TherapyOther: InterviewOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT04705025
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Phase 1
Recruiting
- Conditions
- Stage III Rectal Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIA Rectal Cancer AJCC v8Stage II Rectal Cancer AJCC v8Stage IIB Rectal Cancer AJCC v8Stage IIIC Rectal Cancer AJCC v8Rectal AdenocarcinomaLocally Advanced Rectal CarcinomaStage IIC Rectal Cancer AJCC v8Stage IIIA Rectal Cancer AJCC v8
- Interventions
- Radiation: Intensity-Modulated Radiation TherapyOther: Quality-of-Life AssessmentBehavioral: SurveillanceProcedure: Total Mesorectal Excision
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04703101
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial
Not Applicable
Active, not recruiting
- Conditions
- Prostate AdenocarcinomaStage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8Stage II Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8
- Interventions
- Procedure: DiscussionRadiation: Hypofractionated Radiation TherapyOther: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 226
- Registration Number
- NCT04624256
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Phase 2
Withdrawn
- Conditions
- Clear Cell Papillary Renal NeoplasmHereditary Leiomyomatosis and Renal Cell CarcinomaCollecting Duct CarcinomaMetastatic Unclassified Renal Cell CarcinomaPapillary Renal Cell CarcinomaStage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8Unresectable Renal Cell CarcinomaHereditary Papillary Renal Cell CarcinomaMetastatic Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT04603365
© Copyright 2025. All Rights Reserved by MedPath